Search research articles
Contact Us
Filters
Showing results (31-40 of 77) with videos related to
Page
of 8
Sort By:
The Lancet. Haematology
|
April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
Luis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Clinical Genitourinary Cancer
|
February 21, 2017
Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma
Edouard Auclin, Camille Bourillon, Eleonora De Maio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Nature Cancer
|
May 1, 2026
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
Neeltje Steeghs, Carlos Gomez-Roca, Iphigénie Korakis, et al.
Journal of Neuro-Oncology
|
August 10, 2016
Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
Jonathan Khalifa, Fatima Tensaouti, Jean-Albert Lotterie, et al.
Cancers
|
August 12, 2022
Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
Carlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, et al.
Clinical and Translational Science
|
March 20, 2021
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
Carlos Gomez-Roca, Caroline Even, Christophe Le Tourneau, et al.
Clinical Colorectal Cancer
|
February 28, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
Iván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, et al.
Clinical Lung Cancer
|
December 10, 2017
Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study
Carole Massabeau, Jonathan Khalifa, Thomas Filleron, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 77) with videos related to
Sort By:
Page
of 8
The Lancet. Haematology
|
April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
Luis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Clinical Genitourinary Cancer
|
February 21, 2017
Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma
Edouard Auclin, Camille Bourillon, Eleonora De Maio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Nature Cancer
|
May 1, 2026
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
Neeltje Steeghs, Carlos Gomez-Roca, Iphigénie Korakis, et al.
Journal of Neuro-Oncology
|
August 10, 2016
Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
Jonathan Khalifa, Fatima Tensaouti, Jean-Albert Lotterie, et al.
Cancers
|
August 12, 2022
Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
Carlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, et al.
Clinical and Translational Science
|
March 20, 2021
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
Carlos Gomez-Roca, Caroline Even, Christophe Le Tourneau, et al.
Clinical Colorectal Cancer
|
February 28, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
Iván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, et al.
Clinical Lung Cancer
|
December 10, 2017
Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study
Carole Massabeau, Jonathan Khalifa, Thomas Filleron, et al.
Page
of 8